Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 4:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–17 of 17 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Opaque Bottle Clear all
Completed Phase 2 Interventional Results available

Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis

NCT01154101
View directory record Official record
Conditions
Psoriasis
Interventions
Placebo, SRT2104
Drug
Lead sponsor
Sirtris, a GSK Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
8
States / cities
St Louis, Missouri • New York, New York • Portland, Oregon + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2017 · Synced Sep 3, 2026, 4:24 AM EDT
Recruiting Phase 3 Interventional

Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient

NCT04268849
View directory record Official record
Conditions
Iron Deficiency Anemia
Interventions
Ferumoxytol, Saline, Ferrous sulfate tablets, Vitamin C
Drug
Lead sponsor
Auerbach Hematology Oncology Associates P C
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Sep 3, 2026, 4:24 AM EDT
Completed Not applicable Interventional

Assessing Better Bottles for Babies

NCT06357299
View directory record Official record
Conditions
Pediatric Obesity, Weight Gain Trajectory, Infant Obesity
Interventions
Small Bottle Size, Standard Bottle Size, Clear Bottle, Opaque Bottle
Behavioral
Lead sponsor
Duke University
Other
Eligibility
3 Days to 1 Month
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 3, 2026, 4:24 AM EDT
Completed Phase 1 Interventional

A Phase 1b Study to Assess the Safety and Anti-inflammatory Effects of Two Different Doses of SRT2104 in Patients With Ulcerative Colitis

NCT01453491
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
SRT2104
Drug
Lead sponsor
Sirtris, a GSK Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
13
States / cities
Anaheim, California • Bristol, Connecticut • Owensboro, Kentucky + 10 more
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Sep 3, 2026, 4:24 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation

NCT02163824
View directory record Official record
Conditions
Ocular Infections, Irritations and Inflammations
Interventions
KPI-121 0.25%, KPI-121 1.0%, Vehicle of KPI-121 0.25%, Vehicle of KPI-121 1.0%
Drug
Lead sponsor
Kala Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
23
States / cities
Artesia, California • Mission Hills, California • Rancho Cordova, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Sep 3, 2026, 4:24 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease

NCT02218489
View directory record Official record
Conditions
Blepharitis
Interventions
KPI-121, Vehicle
Drug
Lead sponsor
Kala Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
8
States / cities
Birmingham, Alabama • Artesia, California • Mission Hills, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2021 · Synced Sep 3, 2026, 4:24 AM EDT
Completed Not applicable Interventional Results available

Exploratory Study of KPI-121 Effect on Intra- or Subretinal Fluid Due to Retinal Vein Occlusion/Diabetic Macular Edema

NCT02245516
View directory record Official record
Conditions
Retinal Vein Occlusion, Diabetic Macular Edema
Interventions
KPI-121 0.25% Ophthalmic Suspension, KPI-121 1.0% Ophthalmic Suspension
Drug
Lead sponsor
Kala Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
2
States / cities
Beverly Hills, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced Sep 3, 2026, 4:24 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Opaque Bottle Study

NCT03711370
View directory record Official record
Conditions
Opaque Bottles, Conventional, Clear Bottles
Interventions
Clear Bottle, Opaque Bottle
Other
Lead sponsor
California Polytechnic State University-San Luis Obispo
Other
Eligibility
0 Years to 40 Years
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
San Luis Obispo, California
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Sep 3, 2026, 4:24 AM EDT
Recruiting Phase 2 Interventional

DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma

NCT04696029
View directory record Official record
Conditions
Medulloblastoma
Interventions
Difluoromethylornithine
Drug
Lead sponsor
Giselle Sholler
Other
Eligibility
Up to 21 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
25
States / cities
Little Rock, Arkansas • Oakland, California • Sacramento, California + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 3, 2026, 4:24 AM EDT
Completed Phase 2 Interventional Results available

A New Oral Treatment For Type II Diabetes Mellitus

NCT00111800
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, DEN 2.5 mg, DEN 7.5 mg, DEN 15 mg, DEN 30 mg, DEN 45 mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
36
States / cities
Long Beach, California • Pasadena, California • Denver, Colorado + 32 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2018 · Synced Sep 3, 2026, 4:24 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease

NCT02188160
View directory record Official record
Conditions
Dry Eye Syndromes, Keratoconjunctivitis Sicca
Interventions
KPI-121, Placebo
Drug
Lead sponsor
Kala Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
11
States / cities
Artesia, California • Mission Hills, California • Rancho Cordova, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Sep 3, 2026, 4:24 AM EDT
Enrolling by invitation Phase 2 Interventional

Fingolimod for the Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation

NCT05285878
View directory record Official record
Conditions
Interstitial Fibrosis, Kidney Transplant; Complications, Kidney Transplant Rejection, Kidney Transplant Failure and Rejection, Kidney Transplant Failure, Kidney Failure, Chronic, Graft Rejection
Interventions
Fingolimod, Placebo
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Sep 3, 2026, 4:24 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Influence of Bottle-Type on Infant Feeding Behaviors

NCT02111694
View directory record Official record
Conditions
Conventional Clear Bottle, Opaque Weighted Bottle
Interventions
Bottle Type
Behavioral
Lead sponsor
Drexel University
Other
Eligibility
Up to 6 Months
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 29, 2015 · Synced Sep 3, 2026, 4:24 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Influence of Bottle-Type of Infant Feeding Behavior

NCT02519179
View directory record Official record
Conditions
Bottle Feeding
Interventions
Opaque, weighted bottle, Clear, conventional bottle
Behavioral
Lead sponsor
California Polytechnic State University-San Luis Obispo
Other
Eligibility
Up to 6 Months
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
San Luis Obispo, California
Source: ClinicalTrials.gov public record
Updated Oct 8, 2018 · Synced Sep 3, 2026, 4:24 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Protein Timing and Resistance Exercise on Fat Metabolism

NCT03573687
View directory record Official record
Conditions
Healthy
Interventions
Micellar Casein Protein, Resistance Exercise Training
Dietary Supplement · Other
Lead sponsor
Florida State University
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Sep 3, 2026, 4:24 AM EDT
Not listed Phase 1 Interventional

YL-13027 in Patients With Advanced Solid Tumors

NCT05228600
View directory record Official record
Conditions
Solid Tumor
Interventions
YL-13027
Drug
Lead sponsor
Shanghai YingLi Pharmaceutical Co. Ltd.
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 19, 2022 · Synced Sep 3, 2026, 4:24 AM EDT
Recruiting Phase 3 Interventional

Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis

NCT06950385
View directory record Official record
Conditions
Familial Adenomatous Polyposis (FAP)
Interventions
eRapa (encapsulated rapamycin), Placebo
Drug
Lead sponsor
Rapamycin Holdings Inc.
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
18
States / cities
Arcadia, California • New Haven, Connecticut • Washington D.C., District of Columbia + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 3, 2026, 4:24 AM EDT